Cancer Research and Treatment

Myung Hwan Rho

1 Article

Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis: Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim; Cancer Res Treat. 2008;40(1):22-26. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.22

Purpose

Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined with cisplatin to determine the treatment outcomes for patients with locally advanced or metastatic pancreatic cancer.

Materials and Methods

From 2001 to 2007, we enrolled 60 patients who were treated with gemcitabine or gemcitabine combined with cisplatin for locally advanced or metastatic pancreatic cancer. Gemcitabine 1, 000 mg/m² (G) was administrated at day 1 and day 8 every 3 weeks. Cisplatin 60 mg/m² was added at day 1 every 3 weeks to the gemcitabine schedule (GP).

Results

Number of G: GP was 34: 26, locally advanced to metastatic ratio was 35% to 65% in group G and 46% to 54% in group GP. Median follow up duration was 29 months. The median number of chemotherapy cycles was 4 (range: 2~11) for the G group, and 4 (range: 1~11) for the GP group. The response rate of the G and GP groups was 17% and 11%, respectively. The progression free survival (PFS) was 4.5 months and 2.8 months, respectively, for the G and GP groups. The overall survival (OS) was 10.7 and 8.7 months respectively, for the G and GP groups, but there is no statistically significant difference of the PFS (p=0.2396) and OS (p=0.4643) between the 2 groups. The hematological toxicity profile was similar (the grade III neutropenia and thrombocytopenia was 4.4% and 3.1%, respectively, in G group, and 7.5% and 2.8%, respectively, in the GP group). But non-hematological toxicities such as skin rash, abnormal liver function and nausea/vomiting were observed in 3 patients of the GP group. On the prognostic factor analysis, no factors predicted a longer PFS and OS for both the G and GP groups.

Conclusions

Gemcitabine single treatment might be more tolerable and it had the same efficacy compared to cisplatin combination treatment in this retrospective study.

Citations

Citations to this article as recorded by

Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
David J. Kuter
Haematologica.2022; 107(6): 1243. CrossRef
Treatment of drug-induced immune thrombocytopenias
Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul
Haematologica.2022; 107(6): 1264. CrossRef
Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
Giuseppe Belfiore, Maria Paola Belfiore, Alfonso Reginelli, Raffaella Capasso, Francesco Romano, Giovanni Pietro Ianniello, Salvatore Cappabianca, Luca Brunese
Medical Oncology.2017;[Epub] CrossRef
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Forget
International Journal of Hematology.2017; 106(6): 765. CrossRef
Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam, Yasser Mostafa Kamel
Cancer Medicine.2015; 4(1): 16. CrossRef
Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer
Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao
Clinical Therapeutics.2014; 36(7): 1054. CrossRef
Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
PLoS ONE.2014; 9(8): e104346. CrossRef
Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Samantha B. Kasloff, Matteo S. Pizzuto, Micol Silic-Benussi, Silvia Pavone, Vincenzo Ciminale, Ilaria Capua, K. L. Beemon
Journal of Virology.2014; 88(16): 9321. CrossRef
Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
Wenbo Zhu, Jingjie Li, Sihan Wu, Shifeng Li, Liang Le, Xingwen Su, Pengxin Qiu, Haiyan Hu, Guangmei Yan
Pancreas.2012; 41(7): 1029. CrossRef

11,335 View
57 Download
9 Crossref

Author index